ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1629

AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), autoimmune diseases, B-Cell Targets, Biologicals, interferon

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

Session Type: Abstract Session

Session Time: 9:00AM-10:00AM

Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune diseases. Dual blockade of BAFF and APRIL is proposed to be more effective than targeting either molecule alone. AUR200 is a potent recombinant IgG4 Fc fusion protein containing a modified B cell maturation antigen (BCMA) extracellular domain for enhanced binding to BAFF and APRIL. AUR200 is under development as a next generation therapeutic for B cell-mediated diseases.

Methods: The binding affinity (KD) and half maximal inhibitory concentration (IC50) of AUR200 against human or murine BAFF and APRIL were determined by surface plasmon resonance (Carterra LSA, HC30M sensor chip) and competitive ELISA, respectively. Proliferation was measured with human primary B cells or mouse splenocytes stimulated with BAFF, APRIL or BAFF-60mer. In a therapeutic systemic lupus erythematosus (SLE) study, NZBxNZW F1 mice, randomized by body weight and proteinuria scores, were treated by weekly subcutaneous (SC) injections of AUR200 (1, 3 or 10 mg/kg) from 28 to 34 weeks of age. Urine protein (Albustix® strips) was scored weekly. At week 34, serum antibodies and cytokines were measured by ELISA. Kidneys were formalin-fixed, stained with hematoxylin and eosin, and scored by a board-certified veterinary pathologist. In another study, nonhuman primates (cynomolgus monkeys) received either a single dose (1 mg/kg, SC) or weekly doses (5, 20 or 80 mg/kg, SC) of AUR200 for 4 weeks. Serum immunoglobulins and PBMC B cells were measured. Statistical analyses were performed using one-way ANOVA with Dunnett’s multiple comparison test (GraphPad Prism v9.2).

Results: AUR200 binds human BAFF and APRIL with high affinity and reduces BAFF and APRIL-costimulated proliferation of human primary B cells and mouse splenocytes. AUR200 is more potent than transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)-Fc fusion proteins with similar mechanisms of action (Figure 1). When administered therapeutically in a SLE mouse model, AUR200 significantly improved survival at all doses tested and reduced both proteinuria and histological markers of renal damage. At all doses tested, AUR200 significantly decreased IFNγ and IL-17A, both T cell cytokines, and dose-dependently reduced anti-dsDNA autoantibodies. A single subcutaneous dose of AUR200 in cynomolgus monkeys suppressed peripheral B cells while weekly dosing over 4 weeks resulted in sustained reductions in all serum immunoglobins. Over the month of dosing, AUR200 remained well-tolerated with no adverse findings at any of the doses tested.

Conclusion: AUR200 is a BCMA-IgG4 Fc fusion protein currently in preclinical development. AUR200 demonstrates best in class binding affinity to both BAFF and APRIL due to the engineered modifications to the BCMA binding pocket. In a mouse model of SLE, AUR200 dosed therapeutically reduced several markers of disease activity and improved overall survival. AUR200 was well-tolerated, in both mouse and cynomolgus monkeys, with no adverse effects. These data highlight the potential utility for AUR200 in the treatment of autoimmune diseases.

Supporting image 1

Figure 1. AUR200 potently neutralizes BAFF and APRIL. The binding affinity (KD) of AUR200 against human or murine BAFF and APRIL, determined by surface plasmon resonance (A). The half maximal inhibitory concentration (IC50) of AUR200 against human or murine BAFF and APRIL, determined by competitive ELISA (B). NS, no signal.


Disclosures: S. Morales, Aurinia; J. Cross, aurinia pharmaceuticals; R. Huizinga, Aurinia Pharmaceuticals.

To cite this abstract in AMA style:

Morales S, Cross J, Huizinga R. AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/aur200-an-improved-baff-april-inhibitor-with-increased-potency-and-safety-for-the-treatment-of-b-cell-mediated-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aur200-an-improved-baff-april-inhibitor-with-increased-potency-and-safety-for-the-treatment-of-b-cell-mediated-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology